Netrin-4 Antibody Screening for Neuropathic Pain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropathic pain are inadequate due to the complexity of its molecular mechanisms, and there is a lack of effective medicines, particularly as neuropathic pain is less responsive to conventional pain treatments like nonsteroidal anti-inflammatory drugs and narcotic analgesics.
Innovation Solution
A screening method using netrin-4 and/or its receptor to identify substances that inhibit downstream signaling, which can be used to develop a pharmaceutical composition for pain suppression, including siRNAs and antibodies targeting netrin-4 or its receptor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pain treatments (nonsteroidal anti-inflammatory drugs and narcotic analgesics) are used, then general pain relief is achieved, but they are ineffective for neuropathic pain
Solution Approach 1:
The patent extracts and targets a specific molecular mechanism (netrin-4 signaling pathway) underlying neuropathic pain, rather than using general pain treatments. By identifying netrin-4 as a key mediator in pain transmission and developing antibodies specifically against it, the invention isolates and addresses the specific molecular cause of neuropathic pain that conventional treatments fail to address.
Solution Approach 2:
The patent changes the therapeutic parameter from general anti-inflammatory or analgesic mechanisms to a specific molecular target (netrin-4). By developing antibodies that specifically bind to netrin-4 and blocking its signaling pathway, the invention transforms the approach from broad-spectrum pain management to precision-targeted therapy for neuropathic pain.
2Reliability
If the molecular mechanism of neuropathic pain is investigated deeply, then better treatment strategies can be developed, but the complexity of the mechanism makes radical treatment difficult
Solution Approach 1:
The patent extracts a specific, manageable molecular component (netrin-4) from the complex neuropathic pain mechanism. By focusing on this single key mediator rather than attempting to address the entire complex pathway, the invention simplifies the therapeutic target while maintaining effectiveness against neuropathic pain.
Solution Approach 2:
The patent applies localized intervention by targeting a specific molecular site (netrin-4 signaling) within the broader neuropathic pain pathway. Rather than attempting to modify the entire complex system, the invention introduces a targeted antibody that acts locally at the netrin-4 receptor interaction site, producing therapeutic effect without needing to address the entire molecular complexity.
3Reliability
If netrin-4 signaling is inhibited, then pain suppression is achieved, but screening for effective substances is needed
Solution Approach 1:
The patent performs preliminary action by developing and validating a screening method that uses netrin-4 and its receptor as a model system. By establishing this screening platform in advance, the invention creates a tool that can be used to identify and evaluate potential pain-suppressing substances before clinical application, streamlining the drug development process.
Data Source
AI summary
The present invention provides a screening method for pain suppressors, which method is characterized by using netrin-4 and/or a netrin-4 receptor to select a substance capable of inhibiting downstream signaling from netrin-4. According to the screening method of the present invention, pain suppressors useful as a preventive or therapeutic medicine for pain can be identified. The present invention also provides a pharmaceutical composition for prevention or treatment of pain, which composition comprises, as an active ingredient, a substance capable of inhibiting downstream signaling from netrin-4.